| Entry |
|
|---|
| Name |
Fostamatinib (USAN) |
|---|
| Formula |
C23H26FN6O9P
|
|---|
| Exact mass |
580.1483
|
|---|
| Mol weight |
580.4595
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
Transporter inhibitor
DG01622 ABCB1 inhibitor
DG02862 ABCG2 inhibitor
|
|---|
| Remark |
| Product (DG01419): | D09348<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Immunomodulator, Tyrosin kinase inhibitor |
|---|
| Comment |
Treatment of rheumatoid arthritis, immune thrombocytopenic purpura, and B-cell lymphoma
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04662 | B cell receptor signaling pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
CYP inhibition: CYP3A [HSA: 1576 1577 1551]
Transporter inhibition: ABCB1 [HSA: 5243], ABCG2 [HSA: 9429]
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B02 ANTIHEMORRHAGICS
B02B VITAMIN K AND OTHER HEMOSTATICS
B02BX Other systemic hemostatics
B02BX09 Fostamatinib
D09347 Fostamatinib (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01419 Fostamatinib
D09347 Fostamatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01419 Fostamatinib
D09347 Fostamatinib
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01419 Fostamatinib
D09347 Fostamatinib
Transporter inhibitor
DG01622 ABCB1 inhibitor
DG01419 Fostamatinib
D09347 Fostamatinib
DG02862 ABCG2 inhibitor
DG01419 Fostamatinib
D09347 Fostamatinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
SYK family
SYK
D09347 Fostamatinib (USAN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09347
Drug transporters
D09347
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01419 Fostamatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01419 Fostamatinib
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01419 Fostamatinib
Transporter inhibitor
DG01622 ABCB1 inhibitor
DG01419 Fostamatinib
DG02862 ABCG2 inhibitor
DG01419 Fostamatinib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 40
1 N1b N 19.2868 -25.2551
2 C8y C 19.2868 -23.8526
3 N5x N 18.0947 -23.1513
4 C8x C 18.0947 -21.7488
5 C8y C 19.2868 -21.0475
6 C8y C 20.5491 -21.7488
7 N5x N 20.5491 -23.1513
8 X F 19.2868 -19.6450
9 N1b N 21.7413 -21.0475
10 C8y C 22.9334 -21.7488
11 N5x N 24.1256 -21.0475
12 C8y C 25.3879 -21.7488
13 C8y C 25.3879 -23.1513
14 C8x C 24.1957 -23.8526
15 C8x C 22.9334 -23.1513
16 N1y N 26.5800 -21.0475
17 C5x C 27.7722 -21.7488
18 C1z C 27.7722 -23.1513
19 O2x O 26.5800 -23.8526
20 C1a C 28.9644 -23.8526
21 C1a C 28.9644 -22.4500
22 O5x O 28.9644 -21.0475
23 C1b C 26.5800 -19.6450
24 O2b O 27.7722 -18.9437
25 P1b P 27.7722 -17.5412
26 C8y C 20.5014 -25.9564
27 C8x C 20.5014 -27.3587
28 C8y C 21.7161 -28.0600
29 C8y C 22.9307 -27.3587
30 C8y C 22.9307 -25.9564
31 C8x C 21.7161 -25.2551
32 O2a O 24.1474 -28.0612
33 O2a O 24.1474 -25.2539
34 O2a O 21.7161 -29.4625
35 O1c O 29.1747 -17.5412
36 O1c O 26.3697 -17.5412
37 O1c O 27.7722 -16.1386
38 C1a C 25.3688 -25.9589
39 C1a C 25.3580 -27.3623
40 C1a C 22.9196 -30.1575
BOND 43
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 2
5 5 6 1
6 6 7 2
7 2 7 1
8 5 8 1
9 6 9 1
10 9 10 1
11 10 11 2
12 11 12 1
13 12 13 2
14 13 14 1
15 14 15 2
16 10 15 1
17 12 16 1
18 16 17 1
19 17 18 1
20 18 19 1
21 13 19 1
22 18 20 1
23 18 21 1
24 17 22 2
25 16 23 1
26 23 24 1
27 24 25 1
28 1 26 1
29 26 27 2
30 27 28 1
31 28 29 2
32 29 30 1
33 30 31 2
34 26 31 1
35 29 32 1
36 30 33 1
37 28 34 1
38 25 35 1
39 25 36 1
40 25 37 2
41 33 38 1
42 32 39 1
43 34 40 1
|
|---|
